Jul 10, 2026 06:52AM
Jul 9, 2026 08:30AM
Jul 9, 2026 08:30AM
Jul 6, 2026 08:31AM
Jul 6, 2026 08:30AM
Jun 12, 2026 08:10AM
Jun 4, 2026 08:32AM Fate Therapeutics reports trial data on autoimmune treatments
Jun 4, 2026 08:30AM
Jun 1, 2026 08:30AM
May 21, 2026 08:32AM
May 21, 2026 08:30AM
May 13, 2026 08:30AM
May 11, 2026 08:31AM
May 11, 2026 08:30AM Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
May 5, 2026 08:31AM
May 5, 2026 08:30AM
May 4, 2026 09:00AM
Apr 30, 2026 09:00AM
Mar 18, 2026 11:30AM
Feb 26, 2026 09:00AM
Jan 23, 2026 12:56PM Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Dec 21, 2025 04:00AM
Dec 8, 2025 08:00AM
Dec 8, 2025 08:00AM
Oct 27, 2025 12:29AM
Oct 26, 2025 11:30AM
Sep 3, 2025 06:20AM
Aug 12, 2025 04:01PM Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
Jun 11, 2025 01:00PM
Jun 11, 2025 09:02AM
Jun 11, 2025 09:00AM
May 13, 2025 04:01PM
Apr 14, 2025 08:01AM
Apr 14, 2025 08:00AM
Mar 6, 2025 05:19AM Fate Therapeutics (FATE) PT Lowered to $8 at Jefferies
Mar 5, 2025 04:01PM
Jan 2, 2025 04:00PM
Nov 12, 2024 04:01PM
Aug 13, 2024 04:05PM
May 9, 2024 04:01PM
May 9, 2024 08:38AM
May 9, 2024 08:30AM Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
Nov 8, 2023 04:01PM
Aug 8, 2023 04:01PM
May 3, 2023 04:01PM
Mar 12, 2023 09:00PM
Feb 28, 2023 04:01PM
Feb 28, 2023 04:01PM
Feb 2, 2023 09:47AM GT Biopharma (GTBP) Issues Open Letter to Shareholders Detailing Recent Activities
Feb 2, 2023 09:46AM

326,536 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All